227 related articles for article (PubMed ID: 32626838)
1. Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma.
Choi WM; Choi J; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS; Park SR; Ryu MH; Ryoo BY; Lee SJ; Kim KM
Hepatol Commun; 2020 Jul; 4(7):1073-1086. PubMed ID: 32626838
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
Lee CH; Lee YB; Kim MA; Jang H; Oh H; Kim SW; Cho EJ; Lee KH; Lee JH; Yu SJ; Yoon JH; Kim TY; Kim YJ
Clin Mol Hepatol; 2020 Jul; 26(3):328-339. PubMed ID: 32460459
[TBL] [Abstract][Full Text] [Related]
3. Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.
Lee HJ; Lee JS; So H; Yoon JK; Choi JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Kim DY
Yonsei Med J; 2024 Jul; 65(7):371-379. PubMed ID: 38910299
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure.
Kuo YH; Yen YH; Chen YY; Kee KM; Hung CH; Lu SN; Hu TH; Chen CH; Wang JH
Front Oncol; 2021; 11():683341. PubMed ID: 34136408
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis.
Yang S; Zhou Y; Zeng L
Adv Clin Exp Med; 2023 Aug; 32(8):839-845. PubMed ID: 37140014
[TBL] [Abstract][Full Text] [Related]
6. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing.
Köstek O; Demirel A; Hacıoğlu MB; Tastekin D; Karabulut S; Gündogdu A; Sever N; Ayhan M; Çelebi A; Majidova N; Yaşar A; Ağyol Y; Erel P; Kocaaslan E; Güren AK; Arıkan R; Isık S; Ercelep O; Goksu SS; Alandag C; Bilgetekin İ; Caner B; Sahin AB; Gulmez A; Akagunduz B; Kose F; Kaplan MA; Dogan E; Sakalar T; Guven DC; Gurbuz M; Ergun Y; Karaagac M; Turker S; Ozkul O; Yıldız B; Sahin S; Demiray AG; Sari M; Erdogan B; Hacıbekiroglu İ; Çakmak Öksüzoğlu ÖB; Kilickap S; Bilici A; Bayoglu İV; Topaloglu S; Cicin İ
J Chemother; 2024 Jan; ():1-9. PubMed ID: 38263804
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.
Ren SH; Cui ZL; Lang MR; Li Q; Zhang W; Fang F; Wu Q; Cui YL; Li HK; Chen P; Zhang Y; Song T
J Gastrointest Oncol; 2022 Jun; 13(3):1266-1277. PubMed ID: 35837206
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Finn RS; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Gerolami R; Caparello C; Cabrera R; Chang C; Sun W; LeBerre MA; Baumhauer A; Meinhardt G; Bruix J
J Hepatol; 2018 Aug; 69(2):353-358. PubMed ID: 29704513
[TBL] [Abstract][Full Text] [Related]
9. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Wang HW; Chuang PH; Su WP; Kao JT; Hsu WF; Lin CC; Huang GT; Lin JT; Lai HC; Peng CY
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359658
[TBL] [Abstract][Full Text] [Related]
10. Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting.
Falette-Puisieux M; Nault JC; Bouattour M; Lequoy M; Amaddeo G; Decaens T; Di Fiore F; Manfredi S; Merle P; Baron A; Locher C; Pellat A; Coriat R
Ther Adv Med Oncol; 2023; 15():17588359231189425. PubMed ID: 37547443
[TBL] [Abstract][Full Text] [Related]
11. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
[TBL] [Abstract][Full Text] [Related]
12. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
[TBL] [Abstract][Full Text] [Related]
13. Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma.
Hou JY; Xiao YT; Huang JB; Jiang XH; Jiang K; Li X; Xu L; Chen MS
Front Pharmacol; 2022; 13():917384. PubMed ID: 35734398
[No Abstract] [Full Text] [Related]
14. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice.
Wang W; Tsuchiya K; Kurosaki M; Yasui Y; Inada K; Kirino S; Yamashita K; Sekiguchi S; Hayakawa Y; Osawa L; Okada M; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Enomoto N; Izumi N
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31601010
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice.
Uchikawa S; Kawaoka T; Aikata H; Kodama K; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Hiramatsu A; Tsuge M; Imamura M; Kawakami Y; Chayama K
Hepatol Res; 2018 Sep; 48(10):814-820. PubMed ID: 29682855
[TBL] [Abstract][Full Text] [Related]
17. Combination of systemic immune-inflammation index and albumin-bilirubin grade predict prognosis of regorafenib in unresectable hepatocellular carcinoma.
Teng W; Cheng TA; Lin PT; Lin CC; Lin CY; Lin SM
Am J Cancer Res; 2023; 13(6):2702-2713. PubMed ID: 37424826
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure.
Kim J; Chang JW; Park JY
J Liver Cancer; 2020 Mar; 20(1):72-77. PubMed ID: 37383058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
